Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program for lead asset IMM-1-104 following favorable data against pancreatic cancer.

Immuneering appoints Dr. Igor Matushansky as Chief Medical Officer to enhance clinical development of IMM-1-104 for pancreatic cancer. Immuneering Corporation announced the appointment of Dr. Igor ...

The trial aims to explore the dual-targeting potential of IMM-1-104 in conjunction with immuno-oncology agents such as PD-1 inhibitors. This potential was supported by preclinical data presented ...

“We were delighted to report updates from our ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first ...

Dr. Matushansky joins as Immuneering (IMRX) plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE ...

Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering ...

“We were delighted to report updates from our ongoing Phase 2a trial of IMM-1-104 in January 2025 demonstrating excellent response rates for IMM-1-104 in combination with chemotherapy in first-line ...